Ambrx Biopharma has received 1 bullish and 3 somewhat bullish ratings in the last quarter, indicating a positive outlook for the stock. The average 12-month price target has increased by 111.36% from the previous average, which suggests that analysts are more optimistic about the company's future performance. This positive sentiment is likely to have a short-term positive impact on the stock price.